<SEC-DOCUMENT>0001493152-26-036650.txt : 20260807
<SEC-HEADER>0001493152-26-036650.hdr.sgml : 20260807
<ACCEPTANCE-DATETIME>20260807171156
ACCESSION NUMBER:		0001493152-26-036650
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20260807
DATE AS OF CHANGE:		20260807

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cocrystal Pharma, Inc.
		CENTRAL INDEX KEY:			0001412486
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				352528215
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-87608
		FILM NUMBER:		261255379

	BUSINESS ADDRESS:	
		STREET 1:		19805 N. CREEK PARKWAY
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011
		BUSINESS PHONE:		(786) 459-1831

	MAIL ADDRESS:	
		STREET 1:		19805 N. CREEK PARKWAY
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOZONE PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20110304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	International Surf Resorts, Inc.
		DATE OF NAME CHANGE:	20070917

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FROST PHILLIP MD ET AL
		CENTRAL INDEX KEY:			0000898860
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	MAIL ADDRESS:	
		STREET 1:		4400 BISCAYNE BLVD
		CITY:			MIAMI
		STATE:			FL
		ZIP:			33137-3227
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: FROST PHILLIP MD ET AL -->
          <cik>0000898860</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>8</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.001 per share</securitiesClassTitle>
      <dateOfEvent>08/03/2026</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001412486</issuerCIK>
        <issuerCusips>
          <issuerCusipNumber>19188J409</issuerCusipNumber>
        </issuerCusips>
        <issuerName>Cocrystal Pharma, Inc.</issuerName>
        <address>
          <com:street1>19805 North Creek Parkway,</com:street1>
          <com:city>Bothell</com:city>
          <com:stateOrCountry>WA</com:stateOrCountry>
          <com:zipCode>98011</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Phillip Frost, M.D.</personName>
          <personPhoneNum>(305) 575-6015</personPhoneNum>
          <personAddress>
            <com:street1>Frost Gamma Investments Trust</com:street1>
            <com:street2>4400 Biscayne Boulevard</com:street2>
            <com:city>Miami</com:city>
            <com:stateOrCountry>FL</com:stateOrCountry>
            <com:zipCode>33137</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0000898860</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Phillip Frost, M.D.</reportingPersonName>
        <fundType>PF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>2013876.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>2013876.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>2784719.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>13.9</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>(1) The amounts provided in Item 7 and 9 include (i) 20,325 shares of the Issuer's common stock and (ii) 1,993,551 shares of the Issuer's common stock held by Frost Gamma Investments Trust, which is controlled by Dr. Frost as sole trustee. Does not include options to acquire 51,417 shares of common stock and warrants to acquire 719,426 shares of common stock, both of which are exercisable within 60 days.

(2) The amount provided in Item 11 includes (i) 20,325 shares of common stock owned, (ii) 1,993,551 shares of the Issuer's common stock held by Frost Gamma Investments Trust, which is controlled by Dr. Frost as sole trustee; (iii) options to acquire 51,417 shares of common stock, which are exercisable within 60 days and (iv) 719,426 warrants to acquire shares of common stock, which is controlled by Dr. Frost as sole trustee and are exercisable within 60 days.

(3) The percentage provided in Item 13 is calculated based on (i) 19,263,200 shares of common stock outstanding as of August 3, 2026 and (ii) 51,417 shares of common stock issuable upon exercise of options and 719,426 shares of common stock issuable upon exercise of warrants within 60 days. The percentage reflected in the table above is rounded to the nearest tenth (one place after the decimal point) in accordance with the instructions to Schedule 13D.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001380896</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Frost Gamma Investments Trust</reportingPersonName>
        <fundType>PF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>FL</citizenshipOrOrganization>
        <soleVotingPower>1993551.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>1993551.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>2712977.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>13.5</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
        <commentContent>(1) The amounts provided in Item 7 and 9 include 1,993,551 shares of the Issuer's common stock, which is controlled by Dr. Frost as sole trustee. Does not include warrants to acquire 719,426 shares of common stock, which are exercisable within 60 days.

(2) The amount provided in Item 11 includes (i) 1,993,551 shares of the Issuer's common stock and (ii) 719,426 warrants to acquire shares of the Issuer's common stock, which are exercisable within 60 days. The securities are controlled by Dr. Frost as sole trustee.

(3) The percentage provided in Item 13 is calculated based upon 19,263,200 shares of common stock outstanding as of August 3, 2026 and 719,426 shares of common stock issuable upon exercise of warrants within 60 days. The percentage reflected in the table above is rounded to the nearest tenth (one place after the decimal point) in accordance with the instructions to Schedule 13D.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock, par value $0.001 per share</securityTitle>
        <issuerName>Cocrystal Pharma, Inc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>19805 North Creek Parkway,</com:street1>
          <com:city>Bothell</com:city>
          <com:stateOrCountry>WA</com:stateOrCountry>
          <com:zipCode>98011</com:zipCode>
        </issuerPrincipalAddress>
        <commentText>This Amendment No. 8 on Schedule 13D/A (this "Amendment") is being filed with the Securities and Exchange Commission (the "SEC") on behalf of the Reporting Persons (as defined below) and relates to the common stock, par value $0.001 per share, of Cocrystal Pharma, Inc. (the "Issuer"). This Amendment is being filed as a result of a change in the Reporting Person's beneficial ownership of the common stock, and in the total number of shares of the Issuer's issued and outstanding common stock and, where so stated, amends and supplements Amendment No. 7 to the Schedule 13D and all previous filings on Schedule 13D.</commentText>
      </item1>
      <item2>
        <filingPersonName>This Amendment is filed on behalf of Phillip Frost, M.D. and Frost Gamma Investments Trust (together, the "Reporting Persons").</filingPersonName>
        <principalBusinessAddress>The principal business address of the Reporting Persons is 4400 Biscayne Boulevard, Miami, Florida 33137.</principalBusinessAddress>
        <hasBeenConvicted>During the last five years, none of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).</hasBeenConvicted>
        <convictionDescription>During the last five years, none of the Reporting Persons (or their directors, officers, or controllers, if applicable) have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding were or are subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws.</convictionDescription>
        <citizenship>Dr. Frost is a citizen of the United States of America. Frost Gamma Investments Trust was organized in the State of Florida.</citizenship>
      </item2>
      <item3>
        <fundsSource>On August 3, 2026, the Reporting Persons purchased 75,000 shares of the Issuer's common stock in the open market at $0.9412 per share. On August 5, 2026, the Reporting Persons purchased an additional 10,000 shares of the Issuer's common stock in the open market at $0.9816 per share.</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>The Reporting Persons acquired the shares of common stock for investment purposes.

These securities are held by Frost Gamma Investments Trust, of which Phillip Frost, MD is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole shareholder of Frost-Nevada Corporation. Dr. Frost disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of these securities for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose.</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>The beneficial ownership percentages disclosed below are based on 19,263,200 shares of common stock outstanding as of August 3, 2026, 51,417 shares of common stock issuable upon exercise of options and 719,426 shares of common stock issuable upon exercise of warrants, both within 60 days.

Dr. Frost is the beneficial owner of 2,784,719 shares of common stock representing 13.9% of the shares outstanding of the Issuer, including (i) 1,993,551 shares of common stock held by Frost Gamma Investments Trust, (ii) 20,325 shares of the Issuer's common stock held by the Reporting Person, (iii) 51,417 shares of common stock issuable upon exercise of vested options and (iv) 719,426 shares of common stock issuable upon exercise of warrants. Dr. Frost is the trustee of Frost Gamma Investments Trust. Frost Gamma Limited Partnership is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma Limited Partnership. Dr. Frost is the sole shareholder of Frost-Nevada Corporation, which is the sole shareholder of Frost Gamma, Inc., the general partner of Frost Gamma Limited Partnership. As a result of the foregoing, Dr. Frost may be deemed the beneficial owner of the shares of common stock held by Frost Gamma Investments Trust. Dr. Frost disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein.

Dr. Frost has sole dispositive power with respect to 51,417 shares of common stock issuable upon exercise of vested options.</percentageOfClassSecurities>
        <numberOfShares>The Reporting Persons have voting and dispositive power over the Issuer's securities as described above in Item 5(a).</numberOfShares>
        <transactionDesc>Except as described in this Schedule 13D under Item 3 above, the Reporting Persons did not engage in any transactions in shares of the Company's common stock during the past 60 days.</transactionDesc>
        <listOfShareholders>Not Applicable.</listOfShareholders>
        <date5PercentOwnership>Not Applicable.</date5PercentOwnership>
      </item5>
      <item6>
        <contractDescription>Not Applicable.</contractDescription>
      </item6>
      <item7>
        <filedExhibits>None.</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Phillip Frost, M.D.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Phillip Frost, M.D.</signature>
          <title>Phillip Frost, M.D.</title>
          <date>08/07/2026</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Frost Gamma Investments Trust</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Phillip Frost, M.D.</signature>
          <title>Phillip Frost, M.D., Trustee</title>
          <date>08/07/2026</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
